459
Participants
Start Date
July 31, 2007
Primary Completion Date
May 30, 2018
Study Completion Date
May 30, 2018
Pimavanserin tartrate (ACP-103)
Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
Vienna
Innsbruck
Roeselare
Belgrade
Commack
Albany
Kingston
Marseille
Rochester
Greensburg
Philadelphia
Novi Sad
Vinnitsia
Baltimore
Alexandria
Richmond
Virginia Beach
Roanoke
Durham
Salisbury
Charlotte
New Bern
Asheville
Decatur
Augusta
Ormond Beach
Jacksonville
Panama City
Gainesville
Orlando
Pompano Beach
Deerfield Beach
Miami
Boca Raton
Pessac
Tampa
St. Petersburg
Port Charlotte
Naples
Bradenton
Sarasota
Brentwood
Louisville
Columbus
Toledo
Nantes
Cleveland
Cincinnati
Clinton Township
Roseville
Detroit
West Bloomfield
East Lansing
Traverse City
Milwaukee
Grosseto
Missoula
Glenview
Kharkiv
Springfield
Clermont-Ferrand
St Louis
Columbia
Chieti
Kansas City
Strasbourg
Houston
Lviv
Englewood
Salt Lake City
Tucson
Phoenix
Gilbert
Bydgoszcz
La Habra
Carson
Luhansk
Pasadena
Reseda
La Jolla
Loma Linda
Laguna Hills
Irvine
Fountain Valley
Ventura
Oxnard
Fresno
Sunnyvale
Berkeley
Kirkland
Spokane
Moscow
Saint Petersburg
Smolensk
Pyatigorsk
Kazan'
Samara
Hyderabad
Kirov
Danbury
Fairfield
Farmington
Scarborough
Boston
Worcester
Toms River
Providence
Burlington
London
Ottawa
Bangalore
Chennai
Madurai
Mangalore
Mangalore
Mumbai
Mumbai
Pune
Pune
Visakhapatnam
Rome
Rome
Katowice
Lublin
Coimbra
Lisbon
Porto
Stockholm
Kiev
Kiev
Barnsley
Blackburn
London
Newcastle
North Shields
Lead Sponsor
ACADIA Pharmaceuticals Inc.
INDUSTRY